Olarif

Olopatadine 0.1%

Sterile and Pyrogen free Eye Drops

Composition

Each ml contains Olopatadine Hydrochloride USP equivalent to Olopatadine 1 mg, Preservative: Benzalkonium Chloride BP 0.1 mg.

Description

It is a sterile and pyrogen free ophthalmic solution containing Olopatadine Hydrochloride, a relatively selective H1-receptor antagonist and mast cell stabilizer for topical administration to the eyes.

Clinical Pharmacology

Olopatadine inhibits the release of histamine from the mast cell and is a relatively selective histamine H_1-antagonist that inhibits the in vivo and in vitro type 1 immediate hypersensitivity reaction including inhibition of histamine induced effects on human conjunctival epithelial cells. Olopatadine has no effects on alpha-adrenergic, dopamine and muscarinic type 1 and 2 receptors. Olopatadine was shown to have low systemic exposure after topical administration.

Indications and Usage

This eye drops is indicated for the treatment of signs and symptoms (itchy, watery, red and swollen eyes and/or eyelids) of allergic conjunctivitis including vernal keratoconjunctivitis, vernal keratitis, blepharitis, blepharoconjunctivitis and giant papillary conjunctivitis.

Dosage and Administration

The recommended dose is 1 drop in the affected eye(s) two times daily.

Contraindications

It is contraindicated in persons with a known hypersensitivity to any component of this product.

Precautions

Patients should be advised not to wear a contact lens if their eye is red. Olopatadine ophthalmic solution should not be used to treat contact lens related irritation. Benzalkonium Chloride, preservative of this drops, may be absorbed by soft contact lenses. Patients who wear soft contact lenses and whose eyes are not red should be instructed to wait at least 10 minutes after instillation of this eye drops before they insert their contact lenses. The treatment should be discontinued in the presence of an allergic reaction.

Side-Effects

Rarely headaches have been reported. Other adverse effects: asthenia, blurred vision, burning or stinging, cold syndrome, dry eye, foreign body sensation, hyperemia, hypersensitivity, keratitis, lid edema, nausea, pharyngitis, pruritus, rhinitis, sinusitis and taste perversion.

Use in Pregnancy & Lactation

Olopatadine was found not to be teratogenic in rats and rabbits. There are, however, no adequate and well controlled studies in pregnant women. This drug should be used in pregnant women only if the potential benefit justifies the potential risk to the fetus. It is not known whether topical ocular administration could result in sufficient systemic absorption to produce detectable quantities in the human breast milk. Nevertheless, caution should be exercised when olopatadine is administered to a nursing mother.

Drug Interactions

Specific drug interaction studies have not been conducted with Olopatadine ophthalmic solution.

Overdosage

There is no information on Olopatadine overdose. However, excessive use of any medication can have serious consequences. If you suspect an overdose, seek medical attention without delay.

Pharmaceutical Precautions

Store at room temperature and protect from light. It is desirable that the contents should not be used more than one month after first opening of the bottle.

Commercial Pack

Plastic dropper bottle of 5 ml .

Manufactured by
Popular Pharmaceuticals Ltd. for
BIOPHARMA LIMITED
A-116, BSCIC Industrial Estate
Tongi, Gazipur, Bangladesh

For further query on the use of this medicine, consult to a registered Doctor or Pharmacist.